Joinn Laboratories(China)Co.Ltd Past Earnings Performance
Past criteria checks 1/6
Joinn Laboratories(China)Co.Ltd has been growing earnings at an average annual rate of 37.5%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 34.7% per year. Joinn Laboratories(China)Co.Ltd's return on equity is 4.7%, and it has net margins of 16.7%.
Key information
37.5%
Earnings growth rate
33.8%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 34.7% |
| Return on equity | 4.7% |
| Net Margin | 16.7% |
| Next Earnings Update | 29 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Joinn Laboratories(China)Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,376 | 397 | 315 | 97 |
| 30 Sep 23 | 2,579 | 770 | 311 | 106 |
| 30 Jun 23 | 2,503 | 794 | 316 | 109 |
| 31 Mar 23 | 2,366 | 1,137 | 324 | 93 |
| 31 Dec 22 | 2,268 | 1,074 | 310 | 78 |
| 30 Sep 22 | 1,936 | 941 | 316 | 63 |
| 30 Jun 22 | 1,759 | 775 | 297 | 51 |
| 31 Mar 22 | 1,587 | 589 | 270 | 50 |
| 31 Dec 21 | 1,517 | 557 | 273 | 48 |
| 30 Sep 21 | 1,301 | 419 | 278 | 37 |
| 30 Jun 21 | 1,213 | 379 | 261 | 44 |
| 31 Mar 21 | 1,122 | 389 | 243 | 49 |
| 31 Dec 20 | 1,076 | 315 | 219 | 51 |
| 30 Sep 20 | 922 | 253 | 182 | 62 |
| 30 Jun 20 | 836 | 237 | 159 | 52 |
| 31 Mar 20 | 720 | 194 | 138 | 44 |
| 31 Dec 19 | 639 | 187 | 113 | 40 |
| 30 Sep 19 | 513 | 128 | 106 | 32 |
| 30 Jun 19 | 475 | 126 | 97 | 29 |
| 31 Mar 19 | 432 | 112 | 91 | 25 |
| 31 Dec 18 | 409 | 108 | 85 | 24 |
| 30 Sep 18 | 375 | 99 | 76 | 25 |
| 30 Jun 18 | 341 | 87 | 57 | 36 |
| 31 Mar 18 | 334 | 92 | 56 | 31 |
| 31 Dec 17 | 301 | 76 | 59 | 26 |
| 30 Sep 17 | 294 | 74 | 59 | 19 |
| 31 Dec 16 | 242 | 52 | 66 | 0 |
| 31 Dec 15 | 207 | 49 | 56 | 0 |
| 31 Dec 14 | 185 | 49 | 45 | 0 |
| 31 Dec 13 | 144 | 22 | 43 | 0 |
Quality Earnings: 603127 has a large one-off loss of CN¥226.6M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 603127's current net profit margins (16.7%) are lower than last year (47.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603127's earnings have grown significantly by 37.5% per year over the past 5 years.
Accelerating Growth: 603127's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603127 had negative earnings growth (-63%) over the past year, making it difficult to compare to the Life Sciences industry average (1.1%).
Return on Equity
High ROE: 603127's Return on Equity (4.7%) is considered low.